Zynex (ZYXI) Cash, Cash Equivalents, Marketable Securities : $44.6 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Zynex Cash, Cash Equivalents, Marketable Securities?

Zynex's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($58.75 Mil) to Sep. 2023 ($52.44 Mil) but then stayed the same from Sep. 2023 ($52.44 Mil) to Dec. 2023 ($44.58 Mil).

Zynex's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($42.61 Mil) to Dec. 2022 ($20.14 Mil) but then increased from Dec. 2022 ($20.14 Mil) to Dec. 2023 ($44.58 Mil).

Zynex Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Zynex's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zynex Cash, Cash Equivalents, Marketable Securities Chart

Zynex Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

14.04

39.17

42.61

20.14

44.58

Zynex Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															20.14	16.79	58.75	52.44	44.58

Zynex Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Zynex (NAS:ZYXI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Zynex Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Zynex's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Zynex (ZYXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Zynex Inc (NAS:ZYXI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

9555 Maroon Circle, Englewood, CO, USA, 80112

Website

https://www.zynex.com

Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufacture, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. it also develops and markets medical devices for non-invasive cardiac monitoring, the products of which are under development. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave and others.

Executives

Daniel J Moorhead	officer: Chief Financial Officer	9777 PYRAMID CT, STE 100, ENGLEWOOD CO 80112
Anna Lucsok	officer: See Remarks	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Thomas Sandgaard	director, 10 percent owner, officer: President, CEO and Chairman	10506 KALAHARI CT., LONE TREE CO 80124
Neil Friery	officer: See Remarks	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Joshua R. Disbrow	director	AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Barry D Michaels	director	6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Michael D Cress	director	3409 ESPERANZA CROSSING SUITE 7110, AUSTIN TX 78758
Sandgaard Holdings Llc	10 percent owner	9555 MAROON CIRCLE, ENGLEWOOD CO 80112
Giuseppe Papandrea	officer: Chief Operating Officer	C/O ZYNEX, INC. 9555 MAROON CIRCLE, ENGLEWOOD CO 80112